ICU Medical, Inc. (ICUI) Given Consensus Rating of “Hold” by Brokerages
ICU Medical, Inc. (NASDAQ:ICUI) has received a consensus recommendation of “Hold” from the six analysts that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $232.00.
A number of equities analysts have weighed in on the company. BidaskClub lowered ICU Medical from a “hold” rating to a “sell” rating in a research note on Thursday, August 24th. Zacks Investment Research raised ICU Medical from a “sell” rating to a “hold” rating in a research note on Wednesday, October 11th. Gabelli reissued a “buy” rating on shares of ICU Medical in a research note on Friday, August 11th. Finally, KeyCorp assumed coverage on ICU Medical in a research note on Tuesday, October 17th. They set a “sector weight” rating on the stock.
In other news, Director Joseph R. Saucedo sold 9,000 shares of the company’s stock in a transaction on Monday, October 9th. The stock was sold at an average price of $189.46, for a total value of $1,705,140.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Virginia Ruth Sanzone sold 1,784 shares of the company’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $174.47, for a total value of $311,254.48. Following the completion of the transaction, the vice president now directly owns 102 shares in the company, valued at approximately $17,795.94. The disclosure for this sale can be found here. Insiders have sold 121,447 shares of company stock worth $23,198,692 in the last three months. 13.60% of the stock is currently owned by corporate insiders.
Shares of ICU Medical (ICUI) opened at $203.15 on Wednesday. The company has a market capitalization of $4,090.00, a P/E ratio of 82.80, a P/E/G ratio of 3.39 and a beta of 0.36. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.01 and a current ratio of 4.65. ICU Medical has a 12-month low of $127.00 and a 12-month high of $218.45.
ICU Medical (NASDAQ:ICUI) last released its quarterly earnings data on Thursday, November 9th. The medical instruments supplier reported $1.12 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.77 by $0.35. The company had revenue of $343.20 million for the quarter, compared to analyst estimates of $328.56 million. ICU Medical had a return on equity of 4.81% and a net margin of 2.79%. The firm’s revenue for the quarter was up 253.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.35 earnings per share. analysts predict that ICU Medical will post 3.95 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This report was first posted by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://www.americanbankingnews.com/2017/12/06/icu-medical-inc-icui-given-consensus-rating-of-hold-by-brokerages.html.
About ICU Medical
ICU Medical, Inc is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.
Receive News & Ratings for ICU Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.